LOS ANGELES, February 6, 2018 – ImaginAb Inc., an immuno-oncology imaging company, today announced the appointment of Ian Wilson as the company’s Chief Operating Officer.
Mr. Wilson is an experienced diagnostic veteran with over 25 years of leadership in commercial development of in vivo medical diagnostics and imaging medical devices. From 2004-2017, Mr. Wilson served as CEO and CTO of Edinburgh Molecular Imaging Ltd., where he lead the development of novel optical imaging agents to improve cancer detection, surgery, and lung disease. Previously, he held CTO and COO roles at Xstrahl Ltd. where he was responsible for the oversight of radiotherapy commercial operations and manufacturing, including new product development. Earlier in his career, Ian held various roles of increasing responsibility, including Portfolio and Strategy Manager and Head of Biology, at GE Healthcare. Mr. Wilson holds a MSc Biochemistry from the University of Manchester.
“I’m delighted to announce Ian’s appointment to this new position where he will spearhead our operations, research and development,” said Martyn Coombs, CEO of ImaginAb. “As we progress the development of our ‘first in class’/ CD8 T Cell ImmunoPET imaging agent, Ian’s significant experience and expertise will be instrumental as we work to realize the enormous potential of ImaginAb’s technology for visualizing the immune system response to therapy.”
About ImaginAb
ImaginAb Inc. is an immuno-oncology company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also advancing a best-in-class imaging agent to improve prostate cancer management and patient outcomes, as well as developing a pipeline for other targets in oncology. ImaginAb’s products have the potential to improve patient care and lower healthcare costs.
For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.
Media Contact:
Aram Adajian
Email: AAdajian@imaginab.com
